Provided by Tiger Trade Technology Pte. Ltd.

Definium Therapeutics

37.51
+3.339.74%
Volume:1.17M
Turnover:42.67M
Market Cap:5.04B
PE:-10.77
High:37.53
Open:34.85
Low:34.57
Close:34.18
52wk High:49.70
52wk Low:10.46
Shares:134.37M
Float Shares:129.97M
Volume Ratio:1.02
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4823
EPS(LYR):-2.0600
ROE:-64.09%
ROA:-20.64%
PB:5.49
PE(LYR):-18.21

Loading ...

Definium Therapeutics price target raised to $66 from $57 at RBC Capital

TIPRANKS
·
Aug 17

Definium Therapeutics Price Target Raised to $55.00/Share from $50.00 by Maxim Group

Dow Jones
·
Aug 15

Analysts Conflicted on These Healthcare Names: Definium Therapeutics (DFTX), Ionis Pharmaceuticals (IONS) and Sutro Biopharma (STRO)

TIPRANKS
·
Aug 15

Definium Therapeutics Publishes Corporate Presentation Outlining DT120 ODT Clinical Development Pipeline in Mental Health Indications

Reuters
·
Aug 14

Definium Therapeutics' DT120 Data Boosts Confidence in Future Trials, RBC Capital Markets Says

MT Newswires Live
·
Aug 13

RBC Adjusts PT on Definium Therapeutics to $66 From $57, Keeps Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 13

U.S. Research Roundup-Airbnb, Five Below, Silgan Holdings

Reuters
·
Aug 13

Sector Update: Healthcare Stocks Advance Late Afternoon

MT Newswires Live
·
Aug 13

Definium Therapeutics Price Target Raised to $66.00/Share from $50.00 by Needham

Dow Jones
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Top Midday Stories: Consumer Prices Rise 3.4% YoY in July; CoreWeave Q2 Loss Narrower Than Expectations

MT Newswires Live
·
Aug 12

Ami Fadia Reiterates Buy on Definium (DFTX) as Strong Phase 3 VOYAGE Data Support Unchanged $50 Price Target

TIPRANKS
·
Aug 12

Exchange-Traded Funds, Equity Futures Gain Pre-Bell Wednesday Amid In-Line Consumer Inflation Data, Tech Gains

MT Newswires Live
·
Aug 12

Definium Therapeutics Posts Phase 3 Voyage Topline Results Presentation

Reuters
·
Aug 12

Definium Therapeutics Shares Jump 22% Premarket After Co's Anxiety Disorder Drug Meets Late-Stage Trial Goal

THOMSON REUTERS
·
Aug 12

Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo

MT Newswires Live
·
Aug 12

Definium Therapeutics Says Anxiety Treatment Met Primary Endpoint in Late-Stage Trial

Dow Jones
·
Aug 12

Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 Odt in Generalized Anxiety Disorder

THOMSON REUTERS
·
Aug 12

Definium Therapeutics: Phase 3 Voyage Study of DT120 Odt Met Primary & Key Secondary Efficacy Endpoints

THOMSON REUTERS
·
Aug 12

Definium Therapeutics: Participants on DT120 Odt Achieved Statistically Significant Reduction in Hamilton Anxiety Rating Scale Score

THOMSON REUTERS
·
Aug 12